Navigation Links
Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
Date:11/27/2007

LOUISVILLE, Ky., Nov. 27 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") said today that its Board of Directors declared a regular quarterly dividend of $0.475 per share, payable in cash on December 28, 2007, to stockholders of record on December 7, 2007. The dividend is the fourth quarterly installment of the Company's $1.90 per share 2007 annual dividend.

This fourth quarterly installment of the Company's 2007 annual dividend will be included in stockholders' 2007 taxable income for income tax purposes. More specific information about Ventas's dividends paid in 2007 can be found on its website at http://www.ventasreit.com/investors/dividend.asp.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties. More information about Ventas can be found on its website at http://www.ventasreit.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Ventas, Inc.'s ("Ventas" or the "Company") and its subsidiaries' expected future financial position, results of operations, cash flows, funds from operations, dividends and dividend plans, financing plans, business strategy, budgets, projected costs, capital expenditures, competitive positions, acquisitions, investment opportunities, merger integration, growth opportunities, expected lease income, continued qualification as a real estate investment trust ("REIT"), plans and objectives of management for future operations and statements that include words such as "anti
'/>"/>

SOURCE Ventas, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
2. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
3. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
4. Ventas Appoints Brush SVP - Senior Housing Development and Operations
5. Landauer, Inc. Declares Regular Cash Dividend
6. Weight Watchers Declares Quarterly Dividend
7. Abbott Declares 335th Consecutive Quarterly Dividend
8. HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock
9. Colgate Declares Regular Quarterly Dividends
10. Governor Rendell Declares Senior Smiles Day in Pennsylvania; Goal is to Improve Oral Hygiene for Senior Citizens
11. Mayors Office Declares October 13 as First Metastatic Breast Cancer Awareness Day for New York City
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6